Cross-reactivity of existing equine influenza vaccines with a new strain of equine influenza virus from China.

This research article discusses the emergence of a unique equine influenza virus strain in China and explores potential issues with current vaccines’ effectiveness against this new strain.

Introduction

In the study, researchers have identified a new strain of equine influenza virus, dubbed influenza A/equine/Jilin (China)/1/89. This strain is unique and different from all known strains of equine influenza. This discovery can potentially pose a challenge in animal health as existing vaccines for equine influenza may not be effective in protecting horses against this new strain.

The Issue with Current Vaccines

• This novel strain’s genetic difference may hinder the effectiveness of existing equine influenza vaccines.
• Vaccines are usually designed based on the genetic structure of the prevalent strains. If a new strain arises, and particularly if it is genetically distinct, the vaccine may not offer any protection.

Findings through In Vitro Serological Assays

• The researchers used in vitro (in the lab) serological assays (tests that detect and measure the levels of antibodies in blood) to determine the level of cross-reactivity between the new virus and the existing vaccine strains.
• The concept of ‘cross-reactivity’ here refers to the ability of an immune response (induced by vaccines) to recognize and work against different strains of a pathogen.
• The results, unfortunately, showed low levels of immunological cross-reactivity between the new strain from China and the presently used vaccine strains. This implies that the current vaccines might not efficiently protect against the new virus.
• These results also showed similar low cross-reactivity levels with equine-2 influenza virus strains currently in circulation, further highlighting the potential issue.

In summary, the article focuses on the newly emerged equine influenza virus strain identified in China and the challenges it poses for existing vaccines. The findings suggest a need for newer vaccines or improving the current ones based on the genetic structure of this new strain.